| CEO: | Adrian Kinkaid |
| Chairman: | Simon Gordon Douglas |
| Chief Scientific Officer: | Richard John Buick |
| Non-Executive Dir: | Colin Walsh, Matthew Baker |
| Address: | Springbank Industrial Estate, 1 Springbank Rd, Dunmurry, Belfast, United Kingdom, BT17 0QL |
| Website: | https://www.fusionantibodies.com/ |
| Sector: | Health Care(LSE) |
| Index: | FTSE AIM All-Share |
| ISIN: | GB00BDQZGK16 |
| Currency | UK Pounds |
| Share Price | 10.75p |
| Change Today | -0.25p |
| % Change | -2.27 % |
| 52 Week High | 19.25 |
| 52 Week Low | 6.30 |
| Volume | 22,190 |
| Shares Issued | 125.16m |
| Market Cap | £13.45m |
| RiskGrade | 464 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| No dividends found |
| Time | Volume / Share Price |
| 12:44 | 1,099 @ 11.20p |
| 12:06 | 2,188 @ 11.20p |
| 11:53 | 49 @ 11.50p |
| 11:53 | 13 @ 10.50p |
| 11:53 | 357 @ 10.50p |
| Chair | Simon Gordon Douglas |
| CEO | Adrian Kinkaid |
You are here: research